Synbiotics and probiotics in the critically ill after the PROPATRIA trial

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Purpose of review: Recent clinical trials have furthered our understanding of the role of probiotic and synbiotic therapy across a variety of diverse diseases including antibiotic-associated diarrhea, Clostridium difficile associated diarrhea, acute pancreatitis, ventilator-associated pneumonia, and sepsis among others. Although each of these conditions has implications for critically ill patients, relatively few studies have specifically studied this vulnerable population. Recent findings: One recent clinical trial studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected increase in mortality in probiotic-treated patients. These results stimulated an immediate, extensive, and badly overdue discussion focused on the need for improved safety monitoring during the execution of all clinical trials using probiotics. However, issues with the design, execution, and analysis of PROPATRIA ultimately created more questions than it answered. Summary: Regardless of technical issues with the study, the increased mortality seen with probiotics cannot be ignored. As a result, various regulatory agencies have clarified their stance on the safety of probiotic research and the legacy of PROPATRIA is increasingly stringent regulation of this fledgling niche.

Original languageEnglish
Pages (from-to)147-150
Number of pages4
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume15
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Synbiotics
Probiotics
Critical Illness
Clinical Trials
Pancreatitis
Diarrhea
Safety
Ventilator-Associated Pneumonia
Clostridium difficile
Mortality
Vulnerable Populations
Sepsis
Anti-Bacterial Agents
Research

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Synbiotics and probiotics in the critically ill after the PROPATRIA trial. / Morrow, Lee E.; Gogineni, Vijaya; Malesker, Mark A.

In: Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 15, No. 2, 03.2012, p. 147-150.

Research output: Contribution to journalReview article

@article{b8903be2a55e4a75b4ecbda2dafc104c,
title = "Synbiotics and probiotics in the critically ill after the PROPATRIA trial",
abstract = "Purpose of review: Recent clinical trials have furthered our understanding of the role of probiotic and synbiotic therapy across a variety of diverse diseases including antibiotic-associated diarrhea, Clostridium difficile associated diarrhea, acute pancreatitis, ventilator-associated pneumonia, and sepsis among others. Although each of these conditions has implications for critically ill patients, relatively few studies have specifically studied this vulnerable population. Recent findings: One recent clinical trial studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected increase in mortality in probiotic-treated patients. These results stimulated an immediate, extensive, and badly overdue discussion focused on the need for improved safety monitoring during the execution of all clinical trials using probiotics. However, issues with the design, execution, and analysis of PROPATRIA ultimately created more questions than it answered. Summary: Regardless of technical issues with the study, the increased mortality seen with probiotics cannot be ignored. As a result, various regulatory agencies have clarified their stance on the safety of probiotic research and the legacy of PROPATRIA is increasingly stringent regulation of this fledgling niche.",
author = "Morrow, {Lee E.} and Vijaya Gogineni and Malesker, {Mark A.}",
year = "2012",
month = "3",
doi = "10.1097/MCO.0b013e32834fcea8",
language = "English",
volume = "15",
pages = "147--150",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Synbiotics and probiotics in the critically ill after the PROPATRIA trial

AU - Morrow, Lee E.

AU - Gogineni, Vijaya

AU - Malesker, Mark A.

PY - 2012/3

Y1 - 2012/3

N2 - Purpose of review: Recent clinical trials have furthered our understanding of the role of probiotic and synbiotic therapy across a variety of diverse diseases including antibiotic-associated diarrhea, Clostridium difficile associated diarrhea, acute pancreatitis, ventilator-associated pneumonia, and sepsis among others. Although each of these conditions has implications for critically ill patients, relatively few studies have specifically studied this vulnerable population. Recent findings: One recent clinical trial studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected increase in mortality in probiotic-treated patients. These results stimulated an immediate, extensive, and badly overdue discussion focused on the need for improved safety monitoring during the execution of all clinical trials using probiotics. However, issues with the design, execution, and analysis of PROPATRIA ultimately created more questions than it answered. Summary: Regardless of technical issues with the study, the increased mortality seen with probiotics cannot be ignored. As a result, various regulatory agencies have clarified their stance on the safety of probiotic research and the legacy of PROPATRIA is increasingly stringent regulation of this fledgling niche.

AB - Purpose of review: Recent clinical trials have furthered our understanding of the role of probiotic and synbiotic therapy across a variety of diverse diseases including antibiotic-associated diarrhea, Clostridium difficile associated diarrhea, acute pancreatitis, ventilator-associated pneumonia, and sepsis among others. Although each of these conditions has implications for critically ill patients, relatively few studies have specifically studied this vulnerable population. Recent findings: One recent clinical trial studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected increase in mortality in probiotic-treated patients. These results stimulated an immediate, extensive, and badly overdue discussion focused on the need for improved safety monitoring during the execution of all clinical trials using probiotics. However, issues with the design, execution, and analysis of PROPATRIA ultimately created more questions than it answered. Summary: Regardless of technical issues with the study, the increased mortality seen with probiotics cannot be ignored. As a result, various regulatory agencies have clarified their stance on the safety of probiotic research and the legacy of PROPATRIA is increasingly stringent regulation of this fledgling niche.

UR - http://www.scopus.com/inward/record.url?scp=84857038559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857038559&partnerID=8YFLogxK

U2 - 10.1097/MCO.0b013e32834fcea8

DO - 10.1097/MCO.0b013e32834fcea8

M3 - Review article

C2 - 22248590

AN - SCOPUS:84857038559

VL - 15

SP - 147

EP - 150

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 2

ER -